Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
YEASEN Biotechnology
company
About
YEASEN commitment to developing and producing enzyme products.
- Shanghai,Shanghai,China
- 501 - 1000
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ¥250M
- Industries
- Biotechnology,Health Care,Product Research
- Founded date
- Jan 1, 2014
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Legal Name
- YEASEN Biotechnology (Shanghai) Co., Ltd.
- Also Known As
- YEASEN,YEASEN Biotechnology (Shanghai) Co., Ltd.,lifetopstar
Yeasen is a biotechnology company that provides molecular enzymes, proteins, antibodies, nucleic acids, and cells. They produce fields of life science research, diagnosis and detection, and biomedicine.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥250M
YEASEN Biotechnology has raised a total of
¥250M
in funding over 2 rounds. Their latest funding was raised on
Jun 17, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 17, 2021 | Series B | ¥250M | 2 |
Legend Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
YEASEN Biotechnology is funded by 2 investors.
Legend Capital
and Step Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Legend Capital
|
Yes | Series B |
|
|
— | Series B |
Employee Profiles
Number of Employee Profiles
1
YEASEN Biotechnology has 1 current employee profiles, including
Executive Huang Weihua
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
